Literature DB >> 17488801

Clinical implications of residual growth hormone (GH) response to provocative testing in adults with severe GH deficiency.

Georg Brabant1, Ase Krogh Rasmussen, Beverly M K Biller, Michael Buchfelder, Ulla Feldt-Rasmussen, Kristin Forssmann, Bjorn Jonsson, Maria Koltowska-Haggstrom, Dominique Maiter, Bernhard Saller, Andy Toogood.   

Abstract

CONTEXT: The diagnosis of GH deficiency (GHD) in adults is based on provocative tests of GH release, all influenced by clinical factors. It is unknown whether the amount of residual GH reserve under the cutoff value has any physiological implication.
OBJECTIVES: We used a large pharmacoepidemiological database of adult GHD (KIMS) and tested the impact of confounding factors on GH release of no greater than 3 microg/liter after an insulin tolerance test (ITT) and evaluated its potential physiological role. DESIGN, SETTINGS, AND PATIENTS: A total of 1098 patients fulfilled the criteria of having a GH peak of no greater than 3 microg/liter during ITT as well as documented IGF-I levels. OUTCOMES: The impact of underlying hypothalamic-pituitary disease, age, gender, body weight, as well as treatment modalities such as irradiation on peak GH level to ITT was evaluated, and the correlations between GH peak and targets of GH action were analyzed.
RESULTS: The GH response to ITT was regulated by gender, age, and the number of additional pituitary deficiencies. In a multivariate evaluation, the extent of hypothalamic-pituitary dysfunction was the most important single predictor of GH peak in ITT. GH peaks in ITT were positively related to IGF-I levels and high-density lipoprotein-cholesterol, as well as inversely to triglycerides.
CONCLUSIONS: Even in adult severe GHD, GH release appears to be regulated by factors defined to play an important role in normal GH secretion. The impact of very low GH release on IGF-I and lipid parameters indicates a persistent physiological role of low GH concentrations in severely affected patients with GHD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17488801     DOI: 10.1210/jc.2007-0153

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

Review 1.  Growth hormone treatment in adults with growth hormone deficiency: the transition.

Authors:  M E Molitch
Journal:  J Endocrinol Invest       Date:  2011-01-26       Impact factor: 4.256

2.  [Hypopituitarism in adulthood: diagnosis and therapy].

Authors:  Johannes Hensen
Journal:  Med Klin (Munich)       Date:  2009-03-15

3.  Effects of gender, body weight, and blood glucose dynamics on the growth hormone response to the glucagon stimulation test in patients with pituitary disease.

Authors:  Jessica R Wilson; Andrea L Utz; Jessica K Devin
Journal:  Growth Horm IGF Res       Date:  2015-12-08       Impact factor: 2.372

4.  United States multicenter study of factors predicting the persistence of GH deficiency during the transition period between childhood and adulthood.

Authors:  Charmian A Quigley; Anthony J Zagar; Charlie Chunhua Liu; David M Brown; Carol Huseman; Lynne Levitsky; David R Repaske; Eva Tsalikian; John J Chipman
Journal:  Int J Pediatr Endocrinol       Date:  2013-02-13

Review 5.  Update on GH therapy in adults.

Authors:  Cesar Luiz Boguszewski
Journal:  F1000Res       Date:  2017-11-16

6.  Diagnosis and Treatment of Growth Hormone Deficiency: A Position Statement from Korean Endocrine Society and Korean Society of Pediatric Endocrinology.

Authors:  Jung Hee Kim; Hyun Wook Chae; Sang Ouk Chin; Cheol Ryong Ku; Kyeong Hye Park; Dong Jun Lim; Kwang Joon Kim; Jung Soo Lim; Gyuri Kim; Yun Mi Choi; Seong Hee Ahn; Min Ji Jeon; Yul Hwangbo; Ju Hee Lee; Bu Kyung Kim; Yong Jun Choi; Kyung Ae Lee; Seong-Su Moon; Hwa Young Ahn; Hoon Sung Choi; Sang Mo Hong; Dong Yeob Shin; Ji A Seo; Se Hwa Kim; Seungjoon Oh; Sung Hoon Yu; Byung Joon Kim; Choong Ho Shin; Sung-Woon Kim; Chong Hwa Kim; Eun Jig Lee
Journal:  Endocrinol Metab (Seoul)       Date:  2020-06-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.